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Neuropathic pain is an unpleasant, abnormal signalling associated with injury or 
malfunction in the peripheral or central nervous system (CNS). It has been increasingly 
recognized that glial cells play a critical role in the induction and maintenance of persist-
ent pain. These cells dinamically modulate the function of neurons under both physi-
ological and pathological conditions.
Numerous models of neuropathic pain have indicated that microglia can influence 
development of this phenomenon, e.g. partial sciatic nerve ligation, spinal nerve li-
gation and spinal cord injury. Despite these numerous studies, little is known about 
chemotherapy-based animal models of neuropathic pain. Aim of our study was to better 
characterized the neuropathy elicited by oxaliplatin treatment.
In a rat model of painful oxaliplatin-induced neuropathy (2,4 mgkg-1 intraperitoneal-
ly, daily injected for 21 days), we investigated the influence of this drug on neuropathic 
pain symptoms and the pattern of activation of microglia and astrocytes in CNS. 
Our results showed that all rats with oxaliplatin treatment developed mechanical 
hyperalgesia, mechanical allodynia, cold allodynia and motor coordination impairment. 
To examine whether oxaliplatin induced glia reaction in the spinal cord, we observed 
changes in the expression of Iba-1 and GFAP, markers of reactive gliosis and prolif-
eration of microglia and astrocytes, respectively. Iba-1 expression in the dorsal horn of 
the spinal cord was increased after 21 days treatment compared with the naive condi-
tion, suggesting that oxaliplatin treatment induced a microglia activation. Neverthe-
less, the ramified morphology of this cell type showed the typical resting conformation. 
Increased GFAP immunoreactivity after treatment was seen in expansion of cell body 
size, thickening of the processes and labelling intensity, compared with naive animals, 
suggesting prolonged hyperactivation of astrocytes after injury. Thus Iba-1 and GFAP 
enhanced expressions were also used as a specific functional marker in the brain. The 
pattern of enhanced expression paralleled that of spinal cord and the brain regions 
mainly involved in the hyperactivation were the cyngulate gyrus, putamen, thalamus, 
periaqueductal grey matter, middle forebrain and cerebellum.
Consistent with our findings, many studies suggest that spinal microglia hyperac-
tivation is required for the initiation, but not the maintenance of injury-induced hy-
peralgesia, whereas the prolonged activation of astrocytes plays an important role in 
maintaining neuropathic pain.
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